Megan L Lloyd

Dr. Megan L Lloyd

The University of Western Australia
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2016 in British Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
STStephanie Trend
Stephanie Trend
TSTobias Strunk
Tobias Strunk
MLMegan L Lloyd
Megan L Lloyd
CKChooi Heen Kok
Chooi Heen Kok
JMJessica Metcalfe
Jessica Metcalfe
ACAndrew James Currie
Andrew James Currie
There is a paucity of data on the effect of preterm birth on the immunological composition of breast milk throughout the different stages of lactation. We aimed to characterise the effects of preterm birth on the levels of immune factors in milk during the 1st month postpartum, to determine whether preterm milk is deficient in antimicrobial factors. Colostrum (days 2–5 postpartum), transitional milk (days 8–12) and mature milk (days 26–30) were collected from mothers of extremely preterm (<28 weeks of gestation,n15), very preterm (28–<32 weeks of gestation,n15), moderately preterm (32–<37 weeks of gestation,n15) and term infants (37–41 weeks of gestation,n15). Total protein, lactoferrin, secretory IgA, soluble CD14 receptor (sCD14), transforming growth factor-β2 (TGF-β2),αdefensin 5 (HD5),βdefensins 1 (HBD1) and 2, IL-6, IL-10, IL-13, interferon-γ, TNF-αand lysozyme (LZ) were quantified in milk. We examined the effects of lactation stage, gestational age, volume of milk expressed, mode of delivery, parity and maternal infection on milk immune factor concentrations using repeated-measures regression analysis. The concentrations of all factors except LZ and HD5 decreased over the 1st month postpartum. Extremely preterm mothers had significantly higher concentrations of HBD1 and TGF-β2 in colostrum than term mothers did. After controlling for other variables in regression analyses, preterm birth was associated with higher concentrations of HBD1, LZ and sCD14 in milk samples. In conclusion, preterm breast milk contains significantly higher concentrations of some immune proteins than term breast milk.

19 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
STStephanie Trend
Stephanie Trend
EJEmma de Jong
Emma de Jong
MLMegan L Lloyd
Megan L Lloyd
CKChooi Heen Kok
Chooi Heen Kok
PRPeter C Richmond
Peter C Richmond
ACAndrew James Currie
Andrew James Currie
Extremely preterm infants are highly susceptible to bacterial infections but breast milk provides some protection. It is unknown if leukocyte numbers and subsets in milk differ between term and preterm breast milk. This study serially characterised leukocyte populations in breast milk of mothers of preterm and term infants using multicolour flow cytometry methods for extended differential leukocyte counts in blood. Sixty mothers of extremely preterm (<28 weeks gestational age), very preterm (28–31 wk), and moderately preterm (32–36 wk), as well as term (37–41 wk) infants were recruited. Colostrum (d2–5), transitional (d8–12) and mature milk (d26–30) samples were collected, cells isolated, and leukocyte subsets analysed using flow cytometry. The major CD45+ leukocyte populations circulating in blood were also detectable in breast milk but at different frequencies. Progression of lactation was associated with decreasing CD45+ leukocyte concentration, as well as increases in the relative frequencies of neutrophils and immature granulocytes, and decreases in the relative frequencies of eosinophils, myeloid and B cell precursors, and CD16- monocytes. No differences were observed between preterm and term breast milk in leukocyte concentration, though minor differences between preterm groups in some leukocyte frequencies were observed. Flow cytometry is a useful tool to identify and quantify leukocyte subsets in breast milk. The stage of lactation is associated with major changes in milk leukocyte composition in this population. Fresh preterm breast milk is not deficient in leukocytes, but shorter gestation may be associated with minor differences in leukocyte subset frequencies in preterm compared to term breast milk.

1 June 2003 in Biology of Reproduction
Verified
Journal Article
Open access
PDF file
MLMegan L Lloyd
Megan L Lloyd
GSGeoffrey R. Shellam
Geoffrey R. Shellam
JPJohn M. Papadimitriou
John M. Papadimitriou
MLMalcolm A. Lawson
Malcolm A. Lawson
Immunocontraception, the prevention of oocyte fertilization through immunological means, could potentially be used to control plaguing mouse populati

1 October 2006 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
CHC.M. Hardy
C.M. Hardy
LHLyn A. Hinds
Lyn A. Hinds
PKP.J. Kerr
P.J. Kerr
MLMegan L Lloyd
Megan L Lloyd
ARAlec Redwood
Alec Redwood
TST. Strive
T. Strive

Verified
Journal Article
Open access
PDF file
MFMichelle A. Fisher
Michelle A. Fisher
MLMegan L Lloyd
Megan L Lloyd
Since murine cytomegalovirus (MCMV) was first described in 1954, it has been used to model human cytomegalovirus (HCMV) diseases. MCMV is a natural pathogen of mice that is present in wild mice populations and has been associated with diseases such as myocarditis. The species-specific nature of HCMV restricts most research to cell culture-based studies or to the investigation of non-invasive clinical samples, which may not be ideal for the study of disseminated disease. Initial MCMV research used a salivary gland-propagated virus administered via different routes of inoculation into a variety of mouse strains. This revealed that the genetic background of the laboratory mice affected the severity of disease and altered the extent of subsequent pathology. The advent of genetically modified mice and viruses has allowed new aspects of disease to be modeled and the opportunistic nature of HCMV infection to be confirmed. This review describes the different ways that MCMV has been used to model HCMV diseases and explores the continuing difficulty faced by researchers attempting to model HCMV congenital cytomegalovirus disease using the mouse model.

18 August 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMegan L Lloyd
Megan L Lloyd
NHNurul Hod
Nurul Hod
JJJothsna Jayaraman
Jothsna Jayaraman
EMElizabeth A. Marchant
Elizabeth A. Marchant
LCLukas Christen
Lukas Christen
Karen SimmerKaren Simmer
Karen Simmer
Pasteurized donor human milk is provided by milk banks to very preterm babies where their maternal supply is insufficient or unavailable. Donor milk is currently processed by Holder pasteurization, producing a microbiologically safe product but significantly reducing immunoprotective components. Ultraviolet-C (UV-C) irradiation at 254 nm is being investigated as an alternative treatment method and has been shown to preserve components such as lactoferrin, lysozyme and secretory IgA considerably better than Holder pasteurization. We describe the inactivation of cytomegalovirus, a virus commonly excreted into breast milk, using UV-C irradiation. Full replication was ablated by various treatment doses. However, evidence of viral immediate early proteins within the cells was never completely eliminated indicating that some viral gene transcription was still occurring. In conclusion, UV-C may be a safe alternative to pasteurisation for the treatment of human donor milk that preserves the bioactivity. However, our data suggests that CMV inactivation will have to be carefully evaluated for each device designed to treat breast milk using UV-C irradiation.